Results 51 to 60 of about 10,751 (182)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

BMC Cancer, 2018
Background Ramucirumab has recently proved to be effective for advanced or recurrent gastric cancer (AGC). Ascites and peritoneal metastasis are among the most common complications of AGC.
Hiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Atsushi Ohtsu, Takayuki Yoshino, Toshihiko Doi, Kohei Shitara   +10 more
doaj   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Pharmacoeconomic evaluation of treatment of gastric cancer with ramucirumab in second line

, 2018
We provided a pharmacoeconomic evaluation of the treatment of gastric cancer in the second line of therapy with ramucirumab, using the relative value analysis method.
V.G. Serpik, R.I. Yagudina
core   +1 more source

Ramucirumab: A Review in Hepatocellular Carcinoma

, 2020
Compliance with Ethical StandardsFunding The preparation of this review was not supported by any external funding.Conflicts of interest Yahiya Syed is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content ...
Yahiya Y. Syed (6594444)
core   +1 more source

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

BMC Urology, 2020
Background To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC).
Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, Jae-Lyun Lee, Daniel P. Petrylak, Ronald de Wit, Alexandra Drakaki, Astra M. Liepa, Huzhang Mao, Katherine Bell-McGuinn, Thomas Powles   +10 more
doaj   +1 more source

A Case of Recurrent Gastric Cancer in Which Rheumatoid Arthritis and Sjögren's Syndrome Became Evident With Nivolumab

Clinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT A 59‐year‐old man with recurrent gastric cancer began nivolumab as third‐line therapy and subsequently experienced joint pain and dry eyes. Symptoms worsened despite NSAIDs. He was diagnosed with rheumatoid arthritis and Sjögren's syndrome, associated with nivolumab, and was successfully treated with immunosuppressive and anti‐rheumatic ...
Haruhiko Takemoto, Keiji Nishibeppu, Takeshi Kubota, Hiroyuki Inoue, Kazuya Takabatake, Hirotaka Konishi, Hitoshi Fujiwara, Atsushi Shiozaki   +7 more
wiley   +1 more source

Delayed esophageal anastomotic complication and ramucirumab therapy: A case report

Thoracic Cancer, 2023
Current NCCN guidelines for second‐line therapy in recurrent or metastatic esophago‐gastric cancers recommend the use of VEGF inhibitors such as ramucirumab.
Robert H. Roth, Madison J. Malfitano, Matthew Reilley, Linda W. Martin   +3 more
doaj   +1 more source

Simultaneous Robot‐Assisted Distal Gastrectomy and Radical Cystectomy With a Shared Port Configuration in Situs Inversus Totalis

IJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Situs inversus totalis complicates minimally invasive surgery, and simultaneous robotic surgery for tumors of different organs is particularly challenging. Case Presentation A 72‐year‐old man with situs inversus totalis receiving androgen blockade for prostate cancer developed a 40‐mm muscle‐invasive bladder tumor undetected on ...
Takaharu Hamada, Shugo Yajima, Shota Umezawa, Gaku Okumura, Tomoki Kimura, Shu Gozu, Madoka Kataoka, Yasukazu Nakanishi, Takahiro Kinoshita, Hitoshi Masuda   +9 more
wiley   +1 more source

Clinical utility of ramucirumab in non-small-cell lung cancer

Biologics: Targets & Therapy, 2019
Dipesh UpretyDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USAAbstract: Lung cancer is the leading cause of cancer-related mortality worldwide.
Uprety D
doaj  

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

, 2015
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly ...
Elizabeth Smyth, Ian Chau, Kate Young
core   +1 more source